(Bloomberg) -- Banks including Goldman Sachs Group Inc. and Morgan Stanley are lining up more than €6 billion ($6.5 billion) of debt financing for would—be buyers of Sanofi’s consumer health division, according to people familiar with the matter. Most Read from Bloomberg Biden Vows to Stay in 2024 Race Even as NATO Gaffes Risk His Campaign Biden’s Putin-Zelenskiy Gaffe Deals Fresh Blow to Campaign Tesla Delays Robotaxi Event in Blow to Musk’s Autonomy Drive US and Germany Foiled Russian Plot to Kill CEO of Arms Manufacturer Rheinmetall JPMorgan Notches Record Profit on Visa Gain, Dealmaking Jump The staple financing — pre-arranged funding offered to potential bidders for an acquisition — underscores banks’ appetite to finance leveraged buyouts. Goldman and Morgan Stanley are advising Sanofi on the sale of the $20 billion business. The other advisers, Bank of America Corp. and BNP Paribas SA, also are involved in the financing, said the people, asking not to be identified as the matter is confidential. Any financing for the deal is also expected to include a payment-in-kind loan that could be worth at least €1.5 billion, Bloomberg News reported last month. The PIK arrangement - one of the most borrower-friendly concessions lenders can make - would reduce the upfront interest burden for the company, but it increases the size of the overall debt. Banks don’t tend to underwrite payment-in-kind debt as it is too risky to hold on their balance sheets. Instead, the buyer often opts to go to direct lenders for PIK financing. Goldman, Morgan Stanley, Bank of America and BNP declined to comment. Sanofi declined to comment on the financing, a spokesperson said, adding that the company is keeping all options open to maximize the value of the consumer unit. Sanofi said in October that it aimed to split off the business, either by listing it on the stock market or selling it. A sale of the unit, which sells over-the-counter products including Phytoxil cough syrups and Icy Hot pain relief gels, could rank among one of the biggest deals in Europe this year. First-round bids are due next week, the people said. However, the inconclusive outcome of the French legislative election has made some bidders nervous about committing such a large equity check to a single deal. Traditional lenders are very much back in the market for funding risky transactions. With investors betting that interest rates have peaked, banks are more confident that they can underwrite big acquisitions and then sell the debt on via broadly syndicated loans. Buyout firms, as a result, are increasingly leaning toward banks to finance their deals because the loans are cheaper than those from private credit. If banks win the lending business for the Sanofi unit, bidders would likely look at financing in both dollars and euros, tapping both the high-yield bond and syndicated loan markets, the people said. Most Read from Bloomberg Businessweek How Rivian Became the Anti-Tesla Ukraine Is Fighting Russia With Toy Drones and Duct-Taped Bombs Looser Visa Rules for Indian Travelers Stoke a Tourism Boom Asia Is The New Hot Destination for Luxury Travel At SpaceX, Elon Musk’s Own Brand of Cancel Culture Is Thriving ©2024 Bloomberg L.P.
Banks Plan €6 Billion Debt Financing for Sanofi Consumer Sale
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...